PC
AEGR

Paulson & Co’s Aegerion Pharmaceuticals AEGR Stock Holding History

Paulson & Co’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-26,400
Closed -$267K – 106
2015
Q4 		$267K Buy
+26,400
New +$318K ﹤0.01% 75

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Paulson & Co's AEGR Position: Q1 2016 in Review

Paulson & Co sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2016, closing a stake of 26,400 shares — an estimated $267K sold.

Paulson & Co first reported a position in AEGR in Q4 2015 and held it in 1 quarter. The position peaked at $267K in Q4 2015. 101 funds tracked by Wall St. Rank hold AEGR as of Q1 2016.

  • Paulson & Co reported no remaining Aegerion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Paulson & Co sold 26,400 Aegerion Pharmaceuticals shares in Q1 2016, an estimated $267K.
  • Paulson & Co first reported a position in Aegerion Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Paulson & Co's Aegerion Pharmaceuticals position peaked at $267K in Q4 2015.
  • 101 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2016.

Based on Paulson & Co's 13F filing for Q1 2016, filed 16 May 2016.